Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 43 entries
Sorted by: Best Match Show Resources per page
Serum Selenium Level and 10-Year Survival after Melanoma.

Biomedicines

Rogoża-Janiszewska E, Malińska K, Baszuk P, Marciniak W, Derkacz R, Lener M, Jakubowska A, Cybulski C, Huzarski T, Masojć B, Gronwald J, Rudnicka H, Kram A, Kiedrowicz M, Boer M, Dębniak T, Lubiński J.
PMID: 34440195
Biomedicines. 2021 Aug 11;9(8). doi: 10.3390/biomedicines9080991.

Melanoma is one of the most aggressive human malignancies. The determination of prognostic biomarkers is important for the early detection of recurrence and for the enrollment of the patients into different treatment regimens. Herein, we report the 10-year survival...

Cite
Rogoża-Janiszewska E, Malińska K, Baszuk P, et al. Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines. 2021;9(8)doi: 10.3390/biomedicines9080991.
Rogoża-Janiszewska, E., Malińska, K., Baszuk, P., Marciniak, W., Derkacz, R., Lener, M., Jakubowska, A., Cybulski, C., Huzarski, T., Masojć, B., Gronwald, J., Rudnicka, H., Kram, A., Kiedrowicz, M., Boer, M., Dębniak, T., & Lubiński, J. (2021). Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines, 9(8), . https://doi.org/10.3390/biomedicines9080991
Rogoża-Janiszewska, Emilia, et al. "Serum Selenium Level and 10-Year Survival after Melanoma." Biomedicines vol. 9,8 (2021). doi: https://doi.org/10.3390/biomedicines9080991
Rogoża-Janiszewska E, Malińska K, Baszuk P, Marciniak W, Derkacz R, Lener M, Jakubowska A, Cybulski C, Huzarski T, Masojć B, Gronwald J, Rudnicka H, Kram A, Kiedrowicz M, Boer M, Dębniak T, Lubiński J. Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines. 2021 Aug 11;9(8). doi: 10.3390/biomedicines9080991. PMID: 34440195; PMCID: PMC8392027.
Copy Download .nbib Format: NLM
Recurrent Mutations in .

Cancers

Łukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasiówka M, Blecharz P, Kluz T, Stawicka-Niełacna M, Mądry R, Białkowska K, Prajzendanc K, Kluźniak W, Cybulski C, Dębniak T, Huzarski T, Tołoczko-Grabarek A, Byrski T, Baszuk P, Narod SA, Lubiński J, Jakubowska A.
PMID: 33670479
Cancers (Basel). 2021 Feb 18;13(4). doi: 10.3390/cancers13040849.

The aim of the study was to analyze the frequency and magnitude of association of 21 recurrent founder germline mutations in

Cite
Łukomska A, Menkiszak J, Gronwald J, et al. Recurrent Mutations in . Cancers (Basel). 2021;13(4)doi: 10.3390/cancers13040849.
Łukomska, A., Menkiszak, J., Gronwald, J., Tomiczek-Szwiec, J., Szwiec, M., Jasiówka, M., Blecharz, P., Kluz, T., Stawicka-Niełacna, M., Mądry, R., Białkowska, K., Prajzendanc, K., Kluźniak, W., Cybulski, C., Dębniak, T., Huzarski, T., Tołoczko-Grabarek, A., Byrski, T., Baszuk, P., Narod, S. A., Lubiński, J., & Jakubowska, A. (2021). Recurrent Mutations in . Cancers, 13(4), . https://doi.org/10.3390/cancers13040849
Łukomska, Alicja, et al. "Recurrent Mutations in ." Cancers vol. 13,4 (2021). doi: https://doi.org/10.3390/cancers13040849
Łukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasiówka M, Blecharz P, Kluz T, Stawicka-Niełacna M, Mądry R, Białkowska K, Prajzendanc K, Kluźniak W, Cybulski C, Dębniak T, Huzarski T, Tołoczko-Grabarek A, Byrski T, Baszuk P, Narod SA, Lubiński J, Jakubowska A. Recurrent Mutations in . Cancers (Basel). 2021 Feb 18;13(4). doi: 10.3390/cancers13040849. PMID: 33670479; PMCID: PMC7921976.
Copy Download .nbib Format: NLM
Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework.

International journal of environmental research and public health

Bolte G, Jacke K, Groth K, Kraus U, Dandolo L, Fiedel L, Debiak M, Kolossa-Gehring M, Schneider A, Palm K.
PMID: 34831873
Int J Environ Res Public Health. 2021 Nov 18;18(22). doi: 10.3390/ijerph182212118.

There is a growing awareness about the need to comprehensively integrate sex and gender into health research in order to enhance the validity and significance of research results. An in-depth consideration of differential exposures and vulnerability is lacking, especially...

Cite
Bolte G, Jacke K, Groth K, et al. Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework. Int J Environ Res Public Health. 2021;18(22)doi: 10.3390/ijerph182212118.
Bolte, G., Jacke, K., Groth, K., Kraus, U., Dandolo, L., Fiedel, L., Debiak, M., Kolossa-Gehring, M., Schneider, A., & Palm, K. (2021). Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework. International journal of environmental research and public health, 18(22), . https://doi.org/10.3390/ijerph182212118
Bolte, Gabriele, et al. "Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework." International journal of environmental research and public health vol. 18,22 (2021). doi: https://doi.org/10.3390/ijerph182212118
Bolte G, Jacke K, Groth K, Kraus U, Dandolo L, Fiedel L, Debiak M, Kolossa-Gehring M, Schneider A, Palm K. Integrating Sex/Gender into Environmental Health Research: Development of a Conceptual Framework. Int J Environ Res Public Health. 2021 Nov 18;18(22). doi: 10.3390/ijerph182212118. PMID: 34831873; PMCID: PMC8621533.
Copy Download .nbib Format: NLM
Blood Arsenic Levels as a Marker of Breast Cancer Risk among .

Cancers

Marciniak W, Matoušek T, Domchek S, Paradiso A, Patruno M, Irmejs A, Roderte I, Derkacz R, Baszuk P, Kuświk M, Cybulski C, Huzarski T, Gronwald J, Dębniak T, Falco M, Lener MR, Jakubowska A, Pullella K, Kotsopoulos J, Narod S, Lubiński J.
PMID: 34283078
Cancers (Basel). 2021 Jul 03;13(13). doi: 10.3390/cancers13133345.

An important group of breast cancers is those associated with inherited susceptibility. In women, several predisposing mutations in genes involved in DNA repair have been discovered. Women with a germline pathogenic variant in

Cite
Marciniak W, Matoušek T, Domchek S, et al. Blood Arsenic Levels as a Marker of Breast Cancer Risk among . Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133345.
Marciniak, W., Matoušek, T., Domchek, S., Paradiso, A., Patruno, M., Irmejs, A., Roderte, I., Derkacz, R., Baszuk, P., Kuświk, M., Cybulski, C., Huzarski, T., Gronwald, J., Dębniak, T., Falco, M., Lener, M. R., Jakubowska, A., Pullella, K., Kotsopoulos, J., Narod, S., & Lubiński, J. (2021). Blood Arsenic Levels as a Marker of Breast Cancer Risk among . Cancers, 13(13), . https://doi.org/10.3390/cancers13133345
Marciniak, Wojciech, et al. "Blood Arsenic Levels as a Marker of Breast Cancer Risk among ." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133345
Marciniak W, Matoušek T, Domchek S, Paradiso A, Patruno M, Irmejs A, Roderte I, Derkacz R, Baszuk P, Kuświk M, Cybulski C, Huzarski T, Gronwald J, Dębniak T, Falco M, Lener MR, Jakubowska A, Pullella K, Kotsopoulos J, Narod S, Lubiński J. Blood Arsenic Levels as a Marker of Breast Cancer Risk among . Cancers (Basel). 2021 Jul 03;13(13). doi: 10.3390/cancers13133345. PMID: 34283078; PMCID: PMC8269342.
Copy Download .nbib Format: NLM
DNA testing for variants conferring low or moderate increase in the risk of cancer.

Hereditary cancer in clinical practice

Kurzawski G, Suchy J, Cybulski C, Matyjasik J, Debniak T, Górski B, Huzarski T, Janicka A, Szymanska-Pasternak J, Lubinski J.
PMID: 19804603
Hered Cancer Clin Pract. 2008 Jun 15;6(2):84-7. doi: 10.1186/1897-4287-6-2-84.

No abstract available.

Cite
Kurzawski G, Suchy J, Cybulski C, et al. DNA testing for variants conferring low or moderate increase in the risk of cancer. Hered Cancer Clin Pract. 2008;6(2):84-7doi: 10.1186/1897-4287-6-2-84.
Kurzawski, G., Suchy, J., Cybulski, C., Matyjasik, J., Debniak, T., Górski, B., Huzarski, T., Janicka, A., Szymanska-Pasternak, J., & Lubinski, J. (2008). DNA testing for variants conferring low or moderate increase in the risk of cancer. Hereditary cancer in clinical practice, 6(2), 84-7. https://doi.org/10.1186/1897-4287-6-2-84
Kurzawski, Grzegorz, et al. "DNA testing for variants conferring low or moderate increase in the risk of cancer." Hereditary cancer in clinical practice vol. 6,2 (2008): 84-7. doi: https://doi.org/10.1186/1897-4287-6-2-84
Kurzawski G, Suchy J, Cybulski C, Matyjasik J, Debniak T, Górski B, Huzarski T, Janicka A, Szymanska-Pasternak J, Lubinski J. DNA testing for variants conferring low or moderate increase in the risk of cancer. Hered Cancer Clin Pract. 2008 Jun 15;6(2):84-7. doi: 10.1186/1897-4287-6-2-84. PMID: 19804603; PMCID: PMC2735453.
Copy Download .nbib Format: NLM
Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells.

Stem cells international

Petinati N, Drize N, Sats N, Risinskaya N, Sudarikov A, Drokov M, Dubniak D, Kraizman A, Nareyko M, Popova N, Firsova M, Kuzmina L, Parovichnikova E, Savchenko V.
PMID: 29760731
Stem Cells Int. 2018 Apr 10;2018:6495018. doi: 10.1155/2018/6495018. eCollection 2018.

Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM)...

Cite
Petinati N, Drize N, Sats N, et al. Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. Stem Cells Int. 2018;2018:6495018doi: 10.1155/2018/6495018.
Petinati, N., Drize, N., Sats, N., Risinskaya, N., Sudarikov, A., Drokov, M., Dubniak, D., Kraizman, A., Nareyko, M., Popova, N., Firsova, M., Kuzmina, L., Parovichnikova, E., & Savchenko, V. (2018). Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. Stem cells international, 20186495018. https://doi.org/10.1155/2018/6495018
Petinati, Nataliya, et al. "Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells." Stem cells international vol. 2018 (2018): 6495018. doi: https://doi.org/10.1155/2018/6495018
Petinati N, Drize N, Sats N, Risinskaya N, Sudarikov A, Drokov M, Dubniak D, Kraizman A, Nareyko M, Popova N, Firsova M, Kuzmina L, Parovichnikova E, Savchenko V. Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. Stem Cells Int. 2018 Apr 10;2018:6495018. doi: 10.1155/2018/6495018. eCollection 2018. PMID: 29760731; PMCID: PMC5914104.
Copy Download .nbib Format: NLM
Serum selenium level and cancer risk: a nested case-control study.

Hereditary cancer in clinical practice

Narod SA, Huzarski T, Jakubowska A, Gronwald J, Cybulski C, Oszurek O, Dębniak T, Jaworska-Bieniek K, Lener M, Białkowska K, Sukiennicki G, Muszyńska M, Marciniak W, Sun P, Kotsopoulos J, Lubiński J.
PMID: 31890061
Hered Cancer Clin Pract. 2019 Dec 23;17:33. doi: 10.1186/s13053-019-0131-7. eCollection 2019.

BACKGROUND: Epidemiologic studies have demonstrated a relationship between selenium status and cancer risk among those with low selenium levels. It is of interest to prospectively evaluate the relationship between selenium and cancer among women who reside in a region...

Cite
Narod SA, Huzarski T, Jakubowska A, et al. Serum selenium level and cancer risk: a nested case-control study. Hered Cancer Clin Pract. 2019;17:33doi: 10.1186/s13053-019-0131-7.
Narod, S. A., Huzarski, T., Jakubowska, A., Gronwald, J., Cybulski, C., Oszurek, O., Dębniak, T., Jaworska-Bieniek, K., Lener, M., Białkowska, K., Sukiennicki, G., Muszyńska, M., Marciniak, W., Sun, P., Kotsopoulos, J., & Lubiński, J. (2019). Serum selenium level and cancer risk: a nested case-control study. Hereditary cancer in clinical practice, 1733. https://doi.org/10.1186/s13053-019-0131-7
Narod, Steven A, et al. "Serum selenium level and cancer risk: a nested case-control study." Hereditary cancer in clinical practice vol. 17 (2019): 33. doi: https://doi.org/10.1186/s13053-019-0131-7
Narod SA, Huzarski T, Jakubowska A, Gronwald J, Cybulski C, Oszurek O, Dębniak T, Jaworska-Bieniek K, Lener M, Białkowska K, Sukiennicki G, Muszyńska M, Marciniak W, Sun P, Kotsopoulos J, Lubiński J. Serum selenium level and cancer risk: a nested case-control study. Hered Cancer Clin Pract. 2019 Dec 23;17:33. doi: 10.1186/s13053-019-0131-7. eCollection 2019. PMID: 31890061; PMCID: PMC6929308.
Copy Download .nbib Format: NLM
PALB2 mutations and prostate cancer risk and survival.

British journal of cancer

Wokołorczyk D, Kluźniak W, Stempa K, Rusak B, Huzarski T, Gronwald J, Gliniewicz K, Kashyap A, Morawska S, Dębniak T, Jakubowska A, Szwiec M, Domagała P, Lubiński J, Narod SA, Akbari MR, Cybulski C.
PMID: 34006922
Br J Cancer. 2021 Aug;125(4):569-575. doi: 10.1038/s41416-021-01410-0. Epub 2021 May 18.

BACKGROUND: The objective of this study was to establish the contribution of PALB2 mutations to prostate cancer risk and to estimate survival among PALB2 carriers.METHODS: We genotyped 5472 unselected men with prostate cancer and 8016 controls for two Polish...

Cite
Wokołorczyk D, Kluźniak W, Stempa K, et al. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021;125(4):569-575doi: 10.1038/s41416-021-01410-0.
Wokołorczyk, D., Kluźniak, W., Stempa, K., Rusak, B., Huzarski, T., Gronwald, J., Gliniewicz, K., Kashyap, A., Morawska, S., Dębniak, T., Jakubowska, A., Szwiec, M., Domagała, P., Lubiński, J., Narod, S. A., Akbari, M. R., Cybulski, C. (2021). PALB2 mutations and prostate cancer risk and survival. British journal of cancer, 125(4), 569-575. https://doi.org/10.1038/s41416-021-01410-0
Wokołorczyk, Dominika, et al. "PALB2 mutations and prostate cancer risk and survival." British journal of cancer vol. 125,4 (2021): 569-575. doi: https://doi.org/10.1038/s41416-021-01410-0
Wokołorczyk D, Kluźniak W, Stempa K, Rusak B, Huzarski T, Gronwald J, Gliniewicz K, Kashyap A, Morawska S, Dębniak T, Jakubowska A, Szwiec M, Domagała P, Lubiński J, Narod SA, Akbari MR, Cybulski C. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021 Aug;125(4):569-575. doi: 10.1038/s41416-021-01410-0. Epub 2021 May 18. PMID: 34006922; PMCID: PMC8368211.
Copy Download .nbib Format: NLM
Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility.

Nature genetics

Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, Foulkes WD, Narod SA, Akbari MR.
PMID: 27023777
Nat Genet. 2016 Apr;48(4):473. doi: 10.1038/ng0329-473c.

No abstract available.

Cite
Cybulski C, Carrot-Zhang J, Kluźniak W, et al. Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet. 2016;48(4):473doi: 10.1038/ng0329-473c.
Cybulski, C., Carrot-Zhang, J., Kluźniak, W., Rivera, B., Kashyap, A., Wokołorczyk, D., Giroux, S., Nadaf, J., Hamel, N., Zhang, S., Huzarski, T., Gronwald, J., Byrski, T., Szwiec, M., Jakubowska, A., Rudnicka, H., Lener, M., Masojć, B., Tonin, P. N., Rousseau, F., Górski, B., Dębniak, T., Majewski, J., Lubiński, J., Foulkes, W. D., Narod, S. A., & Akbari, M. R. (2016). Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility. Nature genetics, 48(4), 473. https://doi.org/10.1038/ng0329-473c
Cybulski, Cezary, et al. "Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility." Nature genetics vol. 48,4 (2016): 473. doi: https://doi.org/10.1038/ng0329-473c
Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, Foulkes WD, Narod SA, Akbari MR. Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet. 2016 Apr;48(4):473. doi: 10.1038/ng0329-473c. PMID: 27023777.
Copy Download .nbib Format: NLM
Genetic polymorphisms may influence the vertical growth rate of melanoma.

Journal of Cancer

Sikora M, Rudnicka L, Borkowska B, Kardynał A, Słowińska M, Rakowska A, Warszawik-Hendzel O, Wiergowska A, Ługowska I, Rutkowski P, Dębniak T, Lubiński J, Olszewska M.
PMID: 30210630
J Cancer. 2018 Aug 06;9(17):3078-3083. doi: 10.7150/jca.26404. eCollection 2018.

No abstract available.

Cite
Sikora M, Rudnicka L, Borkowska B, et al. Genetic polymorphisms may influence the vertical growth rate of melanoma. J Cancer. 2018;9(17):3078-3083doi: 10.7150/jca.26404.
Sikora, M., Rudnicka, L., Borkowska, B., Kardynał, A., Słowińska, M., Rakowska, A., Warszawik-Hendzel, O., Wiergowska, A., Ługowska, I., Rutkowski, P., Dębniak, T., Lubiński, J., & Olszewska, M. (2018). Genetic polymorphisms may influence the vertical growth rate of melanoma. Journal of Cancer, 9(17), 3078-3083. https://doi.org/10.7150/jca.26404
Sikora, Mariusz, et al. "Genetic polymorphisms may influence the vertical growth rate of melanoma." Journal of Cancer vol. 9,17 (2018): 3078-3083. doi: https://doi.org/10.7150/jca.26404
Sikora M, Rudnicka L, Borkowska B, Kardynał A, Słowińska M, Rakowska A, Warszawik-Hendzel O, Wiergowska A, Ługowska I, Rutkowski P, Dębniak T, Lubiński J, Olszewska M. Genetic polymorphisms may influence the vertical growth rate of melanoma. J Cancer. 2018 Aug 06;9(17):3078-3083. doi: 10.7150/jca.26404. eCollection 2018. PMID: 30210630; PMCID: PMC6134810.
Copy Download .nbib Format: NLM
Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas.

Hereditary cancer in clinical practice

Cybulski C, Matyjasik J, Soroka M, Szymaś J, Górski B, Debniak T, Jakubowska A, Bernaczyk A, Zimnoch L, Bierzyńska-Macyszyn G, Trojanowski T, Wierzba-Bobrowicz T, Prudlak E, Markowska-Wojciechowska A, Nowacki P, Roszkiewicz A, Kordek R, Szylberg T, Matyja E, Zieliński K, Woźniewicz B, Taraszewska A, Kozłowski W, Lubiński J.
PMID: 20233476
Hered Cancer Clin Pract. 2004 Mar 15;2(2):93-7. doi: 10.1186/1897-4287-2-2-93.

Central nervous system hemangioblastomas (cHAB) are rare tumours which most commonly arise in the cerebellum. Most tumours are sporadic, but as many as one third of cHABs occur in the course of the hereditary disorder - von Hippel-Lindau disease...

Cite
Cybulski C, Matyjasik J, Soroka M, et al. Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas. Hered Cancer Clin Pract. 2004;2(2):93-7doi: 10.1186/1897-4287-2-2-93.
Cybulski, C., Matyjasik, J., Soroka, M., Szymaś, J., Górski, B., Debniak, T., Jakubowska, A., Bernaczyk, A., Zimnoch, L., Bierzyńska-Macyszyn, G., Trojanowski, T., Wierzba-Bobrowicz, T., Prudlak, E., Markowska-Wojciechowska, A., Nowacki, P., Roszkiewicz, A., Kordek, R., Szylberg, T., Matyja, E., Zieliński, K., Woźniewicz, B., Taraszewska, A., Kozłowski, W., & Lubiński, J. (2004). Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas. Hereditary cancer in clinical practice, 2(2), 93-7. https://doi.org/10.1186/1897-4287-2-2-93
Cybulski, Cezary, et al. "Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas." Hereditary cancer in clinical practice vol. 2,2 (2004): 93-7. doi: https://doi.org/10.1186/1897-4287-2-2-93
Cybulski C, Matyjasik J, Soroka M, Szymaś J, Górski B, Debniak T, Jakubowska A, Bernaczyk A, Zimnoch L, Bierzyńska-Macyszyn G, Trojanowski T, Wierzba-Bobrowicz T, Prudlak E, Markowska-Wojciechowska A, Nowacki P, Roszkiewicz A, Kordek R, Szylberg T, Matyja E, Zieliński K, Woźniewicz B, Taraszewska A, Kozłowski W, Lubiński J. Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas. Hered Cancer Clin Pract. 2004 Mar 15;2(2):93-7. doi: 10.1186/1897-4287-2-2-93. PMID: 20233476; PMCID: PMC2840000.
Copy Download .nbib Format: NLM
Principles of genetic predisposition to malignancies.

Hereditary cancer in clinical practice

Debniak T, Lubinski J.
PMID: 19804599
Hered Cancer Clin Pract. 2008 Jun 15;6(2):69-72. doi: 10.1186/1897-4287-6-2-69.

No abstract available.

Cite
Debniak T, Lubinski J. Principles of genetic predisposition to malignancies. Hered Cancer Clin Pract. 2008;6(2):69-72doi: 10.1186/1897-4287-6-2-69.
Debniak, T., & Lubinski, J. (2008). Principles of genetic predisposition to malignancies. Hereditary cancer in clinical practice, 6(2), 69-72. https://doi.org/10.1186/1897-4287-6-2-69
Debniak, Tadeusz, and Lubinski, Jan. "Principles of genetic predisposition to malignancies." Hereditary cancer in clinical practice vol. 6,2 (2008): 69-72. doi: https://doi.org/10.1186/1897-4287-6-2-69
Debniak T, Lubinski J. Principles of genetic predisposition to malignancies. Hered Cancer Clin Pract. 2008 Jun 15;6(2):69-72. doi: 10.1186/1897-4287-6-2-69. PMID: 19804599; PMCID: PMC2735752.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 43 entries